Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Danazol on Endometrial Integrin in RIF
NCT03563664Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Aug 2015
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of danazol in Recurrent Implantation Failure (RIF), sponsored by Ain Shams University. Primary endpoint: H-score of endometrial αvβ3 integrin expression at 12 weeks. Started Aug 2015; status: completed.
02
Drugs
danazol
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT03563664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563664.